| P/E (FY) | — | Sales (TTM) | $6.3M |
| Earnings (TTM) | -$129.9M | ROE | −51.84% |
| Net Margin | −2051.08% | ROIC | — |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | −58.98% |
Fate Therapeutics is a clinical-stage biopharmaceutical company developing programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. Its chimeric antigen receptor (CAR)-targeted NK and T-cell candidates address tumor types, B-cell lymphoma, lupus, autoimmune diseases, and solid tumors, including FT819, FT522, and FT825. It has a collaboration with Ono Pharmaceutical to develop off-the-shelf, iPSC-derived CAR T-cell candidates for solid tumors.
| Market Cap | $270.4M | Trading Days | 3222 |
| 52W High | 3.23 |
| 52W Low | 0.91 |
| % Off High | −28.17% |
| YTD | 136.73% | 1Y | 78.46% |
| 3Y | −44.89% | 5Y | −97.26% |
| 10Y | 17.17% | Since incept. (ann.) | −7.85% |
| Ann. Volatility (1Y) | 98.60% | Ann. Volatility (3Y) | 97.22% |
| Sharpe (1Y) | 1.07 | Sharpe (3Y) | 0.27 |
| Max Drawdown (1Y) | −41.58% | Max Drawdown (3Y) | −91.86% |
| Beta (3Y, vs SPY) | 4.17 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| LCTX | Lineage Cell Therapeutics, Inc. | $266.7M | — |
| AGEN | AGENUS INC | $274.8M | — |
| SABS | SAB Biotherapeutics, Inc. | $263.8M | — |
| ARTV | Artiva Biotherapeutics, Inc. | $260.3M | — |
| EDIT | Editas Medicine, Inc. | $256.5M | — |
| IKT | Inhibikase Therapeutics, Inc. | $305.0M | — |
| AVXL | ANAVEX LIFE SCIENCES CORP. | $238.2M | — |
| NMRA | Neumora Therapeutics, Inc. | $307.6M | — |
| SRZN | Surrozen, Inc./DE | $225.2M | — |
| CHRS | Coherus Oncology, Inc. | $222.1M | 1.0 |
| TARA | Protara Therapeutics, Inc. |
| $214.7M |
| — |
| LXEO | Lexeo Therapeutics, Inc. | $344.7M | — |
